

Physician-reported treatment patterns in moderate to severe Chronic Hand Eczema – the RWEAL multinational medical chart review

Ana Giménez-Arnau¹, Anthony Bewley², Christian Apfelbacher³, Maria Concetta Fagnoli⁴, Bleuenn Rault⁵, Alexanne Morillo⁵, Douglas Maslin⁶, Jenny M. Norlin⁶, Marie-Noëlle Crépy⁷, Sonja Molin^{8,9}

¹Department of Dermatology, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Barcelona, Spain; ²Barts Health NHS Trust & QMUL, London, UK; ³Institute of Social Medicine and Health Systems Research, Otto-von-Guericke University Magdeburg, Magdeburg, Germany; ⁴San Gallicano Dermatological Institute – IRCCS, Rome, Italy; ⁵Oracle Life Sciences, Paris, France; ⁶LEO Pharma A/S, Ballerup, Denmark; ⁷University Hospital of Centre of Paris Department of Occupational and Environmental Diseases, Hotel-Dieu Hospital, and Department of Dermatology, Cochin Hospital, AP-HP, Paris, France; ⁸Department of Dermatology, Venerology and Allergy, Charité-Universitätsmedizin Berlin, Berlin, Germany; ⁹Division of Dermatology, Queen's University, Kingston, ON, Canada.

Corresponding author: Ana Giménez-Arnau, Department of Dermatology, Hospital del Mar, Passeig Maritim de la Barceloneta 25-29, 08003 Barcelona, Spain.

Email: anamariagimenezarnau@gmail.com; 22505aga@comb.cat

Supplementary Table S1. Physician judgment on ongoing topical corticosteroid treatment or reasons for stopping topical corticosteroid treatment at the last visit

	Topical corticosteroid treatment							
	All n=1975		Ultra-high or high potency, n=1228		Medium potency, n=593		Low potency, n=154	
	Ongoing (n=1453)	Stopped (n=522)	Ongoing (n=898)	Stopped (n=330)	Ongoing (n=458)	Stopped (n=135)	Ongoing (n=97)	Stopped (n=57)
Achieved low disease activity state (and completed treatment duration or not)	656 (45.1%)	220 (42.1%)	400 (44.5%)	146 (44.2%)	221 (48.3%)	58 (43.0%)	35 (36.1%)	16 (28.1%)
Failure to maintain a low disease activity state	404 (27.8%)	219 (42.0%)	270 (30.1%)	136 (41.2%)	116 (25.3%)	52 (38.5%)	18 (18.6%)	31 (54.4%)
Lack of treatment adherence	308 (21.2%)	103 (19.7%)	194 (21.6%)	51 (15.5%)	89 (19.4%)	26 (19.3%)	25 (25.8%)	26 (45.6%)
Adverse events or side effects	97 (6.7%)	101 (19.3%)	50 (5.6%)	55 (16.7%)	38 (8.3%)	25 (18.5%)	9 (9.3%)	21 (36.8%)
Other	167 (11.5%)	11 (2.1%)	105 (11.7%)	8 (2.4%)	46 (10.0%)	1 (0.7%)	16 (16.5%)	2 (3.5%)